Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil

Anticancer Research

Volumn 31, Issue 12, 2011, Pages 4665-4671

  Shintani, Yasushi ^a   Inoue, Masayoshi ^a   Funakoshi, Yasunobu ^b   Matsumura, Akihide ^c   Ohta, Mitsunori ^d   Maeda, Hajime ^b   Okumura, Meinoshin ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TONEYAMA NATIONAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

5 fluorouracil; Chemosensitivity; Dihydropyrimidine dehydrogenase; Lung adenocarcinoma; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; TEGAFUR;

ADULT; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 84855166131     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Oguri T, Achiwa H, Bessho Y, Muramatsu H, Maeda H, Niimi T, Sato S and Ueda R: The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49: 345-351, 2005. (Pubitemid 41139147)
2. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004. (Pubitemid 38501140)
3. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M and Wada H: Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small cell lung cancer. J Clin Oncol 23: 4999-5006, 2005. (Pubitemid 46224006)
4. Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M and Niitani H: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multiinstitutional phase II trial. Clin Cancer Res 10: 7860-7864, 2004. (Pubitemid 39587524)
5. Danenberg PV: Thymidylate synthetase: a target enzyme in cancer chemotherapy. Biochem Biophys Acta 473: 73-92, 1977.
6. Jonston PG, Lenz HJ and Leichman CG: Thymidylate syntase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumor. Cancer Res 55: 1407-1412, 1995.
7. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, Maeda H, Kido T, Miyoshi S and Matsuda H: New prognostic indicator for non-small cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 104: 790-795, 2003. (Pubitemid 36418519)
8. Fischel JL, Etienne MC, Spector T, Formento P, Renee N and Milano G: Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin Cancer Res 1: 991-6, 1995.
9. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine Phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
10. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, Maeda H, Kido T, Miyoshi S and Matsuda H: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small cell lung cancer. Lung Cancer 45: 189-196, 2004. (Pubitemid 38891481)
11. Lenz HJ, Leichman CG, and Danenberg KD: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1995. (Pubitemid 26020011)
12. Yamachika T, Nakanishi H, Inada K, Tsukamoto T, Kato T, Fukushima M, Inoue M and Tatematsu M: A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer 82: 70-77, 1998. (Pubitemid 28070481)
13. Harris BE, Song R, Soong SJ and Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990. (Pubitemid 20030018)
14. Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H and Fukushima M: Evaluations of biomarkers associated with 5-FU sensitivity for non-small cell lung cancer patients postoperatively treated with UFT. Br J Cancer 95: 607-615, 2006. (Pubitemid 44325901)
15. Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, Oda M, Sasaki T and Watanabe G: In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep 15: 1533-1539, 2006.
16. Takeda M, Okamoto I, Hirabayashi N, Kitano M and Nakagawa K: Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 73: 103-109, 2011.